Cytosorbents Corp CTSO
Cytosorbents Corp (Nasdaq: CTSO) is a cardio-renal-metabolic medical device company. Its next catalyst on record is CytoSorb (PROCYSS septic shock trial): Complete protocol amendment of paused trial (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: CytoSorb (PROCYSS septic shock trial) — Complete protocol amendment of paused trial (2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| DrugSorb-ATR antithrombotic removal system | Perioperative bleeding in CABG on ticagrelor (FDA De Novo denied; new De Novo planned) | — | NA_NON_THERAPEUTIC |
| CytoSorb | Critical care / cardiac surgery blood purification (CE-marked; US EUA for COVID-19 only; not FDA cleared) | — | NA_NON_THERAPEUTIC |
| ECOS-300CY / PerSorb | Ex vivo organ perfusion (CE-marked) | — | NA_NON_THERAPEUTIC |
| VetResQ | Animal blood purification (veterinary) | — | NA_NON_THERAPEUTIC |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.